CLINICAL OUTCOMES OF NON–SMALL CELL LUNG CANCER PATIENTS WITH BRAF MUTATIONS.
Patients with stage IV non–small-cell lung cancer (NSCLC) and BRAF V600 mutations may benefit from targeted therapies. The French Cooperative Thoracic Intergroup (IFCT) Biomarkers France study was a national prospective cohort study aiming to describe the molecular characteristics and clinical outcome of all consecutive NSCLC patients screened for molecular alterations 83 cases with BRAF mutant […]
CLINICAL OUTCOMES OF NON–SMALL CELL LUNG CANCER PATIENTS WITH BRAF MUTATIONS. Read More »
